Prostatype Genomics: The outcome of the rights issue - Redeye

Prostatype Genomics secured SEK 25m in growth capital in the latest right issue. The new number of shares is 788m with a dilution of 84%. Based on the recent share price, we also include SEK 17m in additional gross funds from the warrants due in April 2024, which could increase the shares to 1,038m. Prostatype Genomics will use the additional funds to cover a bridging loan, secure the ongoing US study, support the US process to ensure US reimbursement by the end of 2024 and general working capital.

Länk till analysen i sin helhet: https://www.redeye.se/research/971151/prostatype-genomics-the-outcome-of-the-rights-issue?utm_source=finwire&utm_medium=RSS